Accelerating Drug Discovery for Frontotemporal Degeneration
Forecasted
Accelerating Drug Discovery for Frontotemporal Degeneration supports researchers and clinicians developing small molecules and biologics to advance disease-modifying treatments for frontotemporal dementia.
Funder: Alzheimer's Drug Discovery Foundation
Due Dates (Anticipated): March 2027 (Letter of Intent) | May 2027 (Invited Full Proposal)
Funding Amounts: Average award of $300,000 for one year, with potential follow-on funding
Summary: Supports small molecule and biologic drug development to advance disease-modifying treatments for frontotemporal dementia.
Key Information: Funding is a mission-related investment requiring a return based on scientific and/or business milestones.
Description
The Alzheimer’s Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) jointly support innovative drug development for frontotemporal dementia (FTD). The program builds on advances in understanding FTD’s pathogenic mechanisms to accelerate disease-modifying therapies, including small molecules and biologics such as antibodies, oligonucleotides, peptides, and gene therapies.
The program funds lead optimization, including medicinal chemistry refinement and in vitro ADME, and testing in relevant animal models. Animal studies may examine novel lead compounds, biologics, vaccines, or repurposed drugs for pharmacokinetics, dose-range finding, target engagement, efficacy, and preliminary rodent tolerability. Other novel targets or pathways are encouraged when compelling evidence establishes a rational biological connection to FTD.
